{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(2)"],"submitter":["Yale JF"],"funding":["Sanofi"],"pubmed_abstract":["<h4>Introduction</h4>For people with type 2 diabetes mellitus who do not achieve glycated hemoglobin A1C targets after treatment with basal insulin therapies, additional therapy with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) may be required. One option is to use a once-daily fixed-ratio combination (FRC) of basal insulin and a GLP-1 RA such as iGlarLixi (which is composed of insulin glargine 100 U/ml and lixisenatide). However, the ease of transitioning from basal insulin to an FRC has not been studied.<h4>Methods</h4>This sub-study of the LixiLan ONE CAN trial (NCT03767543) was conducted to assess the ease of transitioning from insulin glargine 100 U/ml to the FRC, iGlarLixi, using the iGlarLixi SoloStar<sup>®</sup> pen. Patients completed a validated, ten-item questionnaire, "],"journal":["Diabetes therapy : research, treatment and education of diabetes and related disorders"],"pagination":["377-386"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9943797"],"repository":["biostudies-literature"],"pubmed_title":["Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers."],"pmcid":["PMC9943797"],"pubmed_authors":["Stewart J","Hramiak I","Roborel de Climens A","Dex T","Harris S","Aggarwal N","Gerstein HC","Yale JF","Leiter LA"],"additional_accession":[]},"is_claimable":false,"name":"Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers.","description":"<h4>Introduction</h4>For people with type 2 diabetes mellitus who do not achieve glycated hemoglobin A1C targets after treatment with basal insulin therapies, additional therapy with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) may be required. One option is to use a once-daily fixed-ratio combination (FRC) of basal insulin and a GLP-1 RA such as iGlarLixi (which is composed of insulin glargine 100 U/ml and lixisenatide). However, the ease of transitioning from basal insulin to an FRC has not been studied.<h4>Methods</h4>This sub-study of the LixiLan ONE CAN trial (NCT03767543) was conducted to assess the ease of transitioning from insulin glargine 100 U/ml to the FRC, iGlarLixi, using the iGlarLixi SoloStar<sup>®</sup> pen. Patients completed a validated, ten-item questionnaire, ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-04T14:17:52.147Z","creation":"2025-02-19T02:24:05.997Z"},"accession":"S-EPMC9943797","cross_references":{"pubmed":["36574199"],"doi":["10.1007/s13300-022-01353-6"]}}